Profile data is unavailable for this security.
About the company
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
- Revenue in USD (TTM)0.00
- Net income in USD-260.49m
- Incorporated2009
- Employees111.00
- LocationKodiak Sciences Inc1200 PAGE MILL RDPALO ALTO 94304United StatesUSA
- Phone+1 (650) 281-0850
- Fax+1 (302) 636-5454
- Websitehttps://kodiak.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elevation Oncology Inc | 0.00 | -39.35m | 193.42m | 29.00 | -- | 2.41 | -- | -- | -1.03 | -1.03 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -42.35 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -12.50 | 0.2889 | -- | -- | -- | 51.93 | -- | -- | -- |
| Werewolf Therapeutics Inc | 16.22m | -41.58m | 193.81m | 46.00 | -- | 1.64 | -- | 11.95 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| bluebird bio Inc | 21.73m | -91.17m | 194.16m | 323.00 | -- | 0.4905 | -- | 8.94 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
| Veru Inc | 13.48m | -35.82m | 194.69m | 189.00 | -- | 4.31 | -- | 14.44 | -0.3465 | -0.3465 | 0.1267 | 0.3089 | 0.1898 | 1.42 | 3.86 | 71,318.68 | -50.43 | -42.91 | -76.84 | -54.41 | 34.13 | 72.41 | -265.74 | -104.96 | 4.22 | -- | 0.177 | -- | -58.59 | 0.5394 | -10.84 | -- | 67.39 | -- |
| INmune Bio Inc | 155.00k | -30.01m | 196.24m | 11.00 | -- | 4.67 | -- | 1,266.08 | -1.67 | -1.67 | 0.0086 | 2.12 | 0.0022 | -- | 0.0284 | 14,090.91 | -43.24 | -37.82 | -54.85 | -41.86 | -- | -- | -19,360.00 | -14,901.03 | -- | -13.06 | 0.2064 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -13.07m | 197.20m | 1.00 | -- | 55.42 | -- | -- | -0.48 | -0.48 | 0.00 | 0.1202 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.40 | 0.0285 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| P3 Health Partners Inc | 1.27bn | -57.77m | 199.05m | 400.00 | -- | 0.5169 | -- | 0.1572 | -0.6494 | -0.6494 | 13.37 | 1.22 | 1.46 | -- | 13.23 | 3,165,938.00 | -21.46 | -- | -96.06 | -- | 2.50 | 0.1781 | -14.72 | -56.93 | -- | -10.33 | 0.1999 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Kodiak Sciences Inc | 0.00 | -260.49m | 201.21m | 111.00 | -- | 0.7567 | -- | -- | -4.97 | -4.97 | 0.00 | 5.06 | 0.00 | -- | -- | 0.00 | -45.46 | -31.73 | -49.53 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| CervoMed Inc | 7.14m | -2.17m | 201.80m | 8.00 | -- | 18.81 | -- | 28.24 | -0.6282 | -0.6282 | 2.07 | 1.30 | 0.4382 | -- | -- | 893,108.80 | -13.32 | -53.67 | -15.74 | -58.89 | -- | -- | -30.40 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -52.37m | 201.87m | 51.00 | -- | 0.7288 | -- | -- | -1.08 | -1.08 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -20.67 | -- | -21.56 | -- | -- | -- | -- | -- | -- | -- | 0.103 | -- | -- | -- | -22.20 | -- | -- | -- |
| Zevra Therapeutics Inc | 28.01m | -50.90m | 204.65m | 65.00 | -- | 4.19 | -- | 7.31 | -1.34 | -1.34 | 0.7513 | 1.17 | 0.2172 | -- | 3.47 | 430,876.90 | -39.48 | -32.11 | -47.94 | -39.89 | 51.11 | -- | -181.75 | -128.42 | -- | -- | 0.4648 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Lineage Cell Therapeutics Inc | 8.00m | -23.66m | 205.79m | 75.00 | -- | 2.84 | -- | 25.71 | -0.1344 | -0.1344 | 0.0455 | 0.3836 | 0.0722 | -- | 57.16 | 106,706.70 | -21.32 | -19.53 | -24.82 | -22.59 | 91.88 | 89.13 | -295.30 | -370.88 | -- | -- | 0.0018 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| Prelude Therapeutics Inc | 0.00 | -125.55m | 208.73m | 128.00 | -- | 0.9904 | -- | -- | -1.88 | -1.88 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -56.37 | -47.21 | -61.52 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Zura Bio Ltd | 0.00 | -69.24m | 208.81m | 14.00 | -- | 3.52 | -- | -- | -4.38 | -4.38 | 0.00 | 1.36 | 0.00 | -- | -- | 0.00 | -49.98 | -- | -60.56 | -- | -- | -- | -- | -- | -- | -- | 0.0123 | -- | -- | -- | -2,050.99 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Kodiak Sciences Inc's reporting currency: US Dollar USD
57.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Mar 2024 | 17.31m | 32.96% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.83m | 5.39% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 1.72m | 3.28% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.63m | 3.10% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 1.61m | 3.07% |
| SilverArc Capital Management LLCas of 31 Mar 2024 | 1.24m | 2.36% |
| D. E. Shaw & Co. LPas of 31 Mar 2024 | 1.04m | 1.99% |
| ICONIQ Capital LLCas of 31 Mar 2024 | 1.02m | 1.94% |
| Newtyn Management LLCas of 31 Mar 2024 | 1.00m | 1.90% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 781.54k | 1.49% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
